At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,769 enrolled
Drug / intervention
Sunitinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors (TKI) on Clinical Outcomes Among Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received First-Line Sunitinib in the International mRCC Database Consortium (IMDC) Based on Prognostic Risk Score
In Brief
An observational study evaluating Sunitinib for Metastatic Renal Cell Carcinoma. Completed, enrolled 1,769 participants across 1 site.
Detailed Summary
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesCanada
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartSep 2018
Primary CompletionSep 2018
First PostedSep 2019
TodayJul 2026
First PostedSep 3, 2019
Enrollment StartSep 1, 2018
Primary CompletionSep 2, 2018
TodayJul 2, 2026
Enrollment to primary: 1 daysPosted 6.8 years ago
Interventions
Sunitinibdrug
patients who received sunitinib as first line therapy for mRCC